Medicare quietly guarantees full reimbursement for pharmacy fee hike

What it does

This bill requires Medicare prescription drug plans to pay long-term care pharmacies an additional $30 per prescription in 2026 (and inflation-adjusted amounts in 2027), on top of existing reimbursements. The government will fully reimburse plans for these new fees, and the bill directs a study on whether long-term care pharmacies can sustainably participate in Medicare.

Why we flagged it

The bill's core mechanism is a mandated per-prescription fee paid by Medicare plans to long-term care pharmacies, fully reimbursed by the government. This is a targeted subsidy to a specific pharmacy sector, not a broad patient-access reform.

What the text implies

• The full reimbursement guarantee (Section 1860D–15) means insurers bear zero net cost, eliminating any incentive to negotiate or control the fee. The cost is entirely absorbed by Medicare, raising premiums or reducing other benefits.
• The bill applies only to 'specified prescriptions' (those at maximum fair price under Section 1193), creating a narrow carve-out that may not address broader long-term care pharmacy viability.
• No sunset clause or performance metrics: the fee continues indefinitely unless Congress acts, locking in a permanent cost increase with no requirement to demonstrate patient benefit.
• The GAO study (due 12 months post-enactment) is advisory only; Congress is not required to act on its findings, making it a symbolic gesture rather than a trigger for policy adjustment.
• Rural market language suggests the bill may be responding to pharmacy closures, but the mechanism (a flat per-prescription fee) does not target rural areas specifically or address underlying structural problems.

Who it affects

Seniors in long-term care may benefit from improved pharmacy access and service continuity if the fee prevents closures. However, the cost is shifted to all Medicare beneficiaries (via higher premiums or general revenue), and the bill guarantees full reimbursement to insurers, meaning no real cost control — the fee is essentially a hidden subsidy with no sunset or performance requirement.

Who stands to gain

• long-term care pharmacies
• pharmacy benefit managers (PBMs) managing MA-PD plans
• Medicare Advantage organizations (indirect, via reimbursement guarantee)

Named in the bill

long-term care pharmacies, PDP sponsors, MA organizations, Medicare Part D, Social Security Act Section 1860D–4, Social Security Act Section 1860D–15, Comptroller General (GAO), HHS Secretary, National Uniform Claim Committee

Where it stands

4 cosponsors: 4 Republicans.

• Nov 7, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Nov 7, 2025 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

12 lobbying clients named this bill on 18 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $2,050,000 in lobbying spend. A filing names 2 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 93% of bills with at least one filing.

James Lankford, the sponsor, reported $368,500 in PAC receipts in the 2026 cycle.

• Cardinal Health Inc — $460,000 on 1 filing
• Senior Care Pharmacy Coalition — $320,000 on 1 filing
• National Community Pharmacists Association — $270,000 on 1 filing
• Senior Care Pharmacy Coalition — $180,000 on 2 filings
• Brightspring Health Services — $160,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.